Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • U.S. Psychedelic Policy Reform
    • Worldwide Psychedelic Laws
    • Oregon Psilocybin Services Tracker
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Oregon Psilocybin Services Tracker: Q1 2025

Oregon Psilocybin Services Tracker: Q1 2025

  • Post published:July 4, 2025
  • Post category:Analysis/Pα+
Read more about the article Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

  • Post published:July 1, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

  • Post published:July 1, 2025
  • Post category:Analysis/News
Read more about the article Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

  • Post published:June 28, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

  • Post published:June 25, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

  • Post published:June 23, 2025
  • Post category:Analysis/News
Read more about the article Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

  • Post published:June 18, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

  • Post published:June 2, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials

  • Post published:May 28, 2025
  • Post category:Analysis/News
Read more about the article Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study

  • Post published:May 27, 2025
  • Post category:Analysis/News/Pα+

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More